Floatz logo

Glatiramer

Carcinoma, Ovarian Epithelial

Institut du Cancer de Montpellier - Val d'Aurelleprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Carcinoma, Ovarian Epithelial cohort.

Asset / SponsorPhaseRating
LENVATINIB
University Medical Center Groningen
Phase 4BB
Catequentinib
Lei Li
Phase 3BB
kfa115
Novartis Pharmaceuticals
Phase 1CC
bp1001-a
Bio-Path Holdings, Inc.
Phase 1CC
ab-1015
Arsenal Biosciences, Inc.
Phase 1CC

View all 11 →

Same molecule, other indications

Glatiramer is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
79 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
67 / 100
View asset →
secondary progressive multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →